Clinical Trial comparing the Effectiveness of Magnesium Sulfate and Lidocaine Nebulizers in Reducing Cough in Patients Undergoing Bronchoscopy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251018067675N1

Enrollment

Registered

2025-11-29

Start date

2025-11-06

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coughing during bronchoscopy.

Interventions

Intervention 1: Intervention group: A. Intervention 2: Intervention group: B. Intervention 3: Control group: C.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients completing the consent form Adult patients over 18 years of age and under 65 years of age Patients undergoing fiberoptic bronchoscopy and bronchoalveolar lavage

Exclusion criteria

Exclusion criteria: Patients who require procedures beyond bronchoalveolar lavage (biopsy and bronchoscopic procedures) Patients with decompensated heart failure Advanced liver failure End-stage renal disease patients Pregnant and breastfeeding women Patients who have taken magnesium supplements and lidocaine in the past month Patients with a history of drug sensitivity to magnesium and lidocaine Patients with tracheostomy

Design outcomes

Primary

Measure	Time frame
Cough. Timepoint: During the procedure. Method of measurement: Visual Analogue Scale (VAS).	—

Secondary

Measure	Time frame
Patient satisfaction. Timepoint: Half an hour after the procedure. Method of measurement: Visual Analogue Scale (VAS).;How long does it take for a bronchoscopy. Timepoint: During the procedure. Method of measurement: Time.;Duration of passage through the vocal cords. Timepoint: During the procedure. Method of measurement: Time.;Hemodynamic changes including heart rate, respiratory rate and blood pressure. Timepoint: Ten minutes before and half an hour after the procedure. Method of measurement: Pressure measurement and counting of beats per minute.;Average SPO2 changes. Timepoint: Ten minutes before and half an hour after the procedure. Method of measurement: Pulse oximeter.;The rate of adverse events included uncontrolled bleeding, cardiorespiratory arrest, need for intubation, and mortality. Timepoint: During and up to half an hour after the procedure. Method of measurement: observation.;Type and dose of intravenous sedatives required. Timepoint: During the procedure. Method of measurement: observation.	—

Measure

Time frame

Patient satisfaction. Timepoint: Half an hour after the procedure. Method of measurement: Visual Analogue Scale (VAS).;How long does it take for a bronchoscopy. Timepoint: During the procedure. Method of measurement: Time.;Duration of passage through the vocal cords. Timepoint: During the procedure. Method of measurement: Time.;Hemodynamic changes including heart rate, respiratory rate and blood pressure. Timepoint: Ten minutes before and half an hour after the procedure. Method of measurement: Pressure measurement and counting of beats per minute.;Average SPO2 changes. Timepoint: Ten minutes before and half an hour after the procedure. Method of measurement: Pulse oximeter.;The rate of adverse events included uncontrolled bleeding, cardiorespiratory arrest, need for intubation, and mortality. Timepoint: During and up to half an hour after the procedure. Method of measurement: observation.;Type and dose of intravenous sedatives required. Timepoint: During the procedure. Method of measurement: observation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSayyed Abolfazl Makky Nezhad

Yazd University of Medical Sciences

Makkynezhad@gmail.com+98 913 951 5614

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026